We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
+53.88%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$304M
AUM Growth
+$102M
Cap. Flow
+$7.74M
Cap. Flow %
2.55%
Top 10 Hldgs %
100%
Holding
10
New
–
Increased
1
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$22.1M

Top Sells

Rank Stock Value
1
BOLD
Audentes Therapeutics, Inc
BOLD
+$11.5M
2
IMDZ
Immune Design Corp.
IMDZ
+$2.87M

Sector Composition

Rank Sector Weight
1 Healthcare 99.79%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.68B
$152M 50%
4,248,888
+640,014
+18% +$22.1M
VCYT icon
2
Veracyte
VCYT
$4.44B
$90.5M 29.8%
3,616,221
– –
BOLD
3
DELISTED
Audentes Therapeutics, Inc
BOLD
$31.3M 10.32%
803,106
-401,509
-33% -$11.5M
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
$14.4M 4.76%
1,084,696
– –
OCUL icon
5
Ocular Therapeutix
OCUL
$1.85B
$8.8M 2.9%
2,215,384
– –
VANI icon
6
Vivani Medical
VANI
$113M
$3.57M 1.18%
187,207
– –
CLVS
7
DELISTED
Clovis Oncology, Inc.
CLVS
$2.53M 0.83%
101,855
– –
AKAO
8
DELISTED
Achaogen Inc
AKAO
$585K 0.19%
1,281,152
– –
OPGN
9
DELISTED
OpGen, Inc
OPGN
$61.7K 0.02%
26
– –
IMDZ
10
DELISTED
Immune Design Corp.
IMDZ
– –
-2,208,210
Closed -$2.87M

Similar funds

POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
RB
Renasant Bank Tupelo, Mississippi $141M AUM 16.9% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
CFGW
Chancellor Financial Group WB Wilkes-Barre, Pennsylvania $141M AUM 23.22% 1-Year Est. Return

Versant Venture Management's Q1 2019 Portfolio in Review

As of Q1 2019, Versant Venture Management held 10 positions worth $304M, up 50% from $202M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management's Q1 2019 filing shows 1 increased, 1 reduced and 1 closed positions. The largest sale was Audentes Therapeutics, Inc, an estimated $11.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier.

  • Versant Venture Management added most to CRISPR Therapeutics in Q1 2019, an estimated $22.1M increase.
  • Versant Venture Management's biggest Q1 2019 reduction was Audentes Therapeutics, Inc, cutting an estimated $11.5M.
  • Versant Venture Management fully exited Immune Design Corp. in Q1 2019, selling an estimated $2.87M.
  • Versant Venture Management's ten largest holdings make up 100% of its $304M portfolio in Q1 2019.
  • Versant Venture Management opened 0 new positions and closed 1 in Q1 2019.
  • Versant Venture Management's portfolio value rose 50% quarter-over-quarter to $304M.

Based on Versant Venture Management's 13F filing for Q1 2019, filed 5 Apr 2019.